石杉碱甲胶囊和片剂治疗阿尔采末病的多中心双盲研究

Huperzine A capsules vs tablets in treatment of Alzheimer disease: multicenter studies

目的：比较石杉碱甲胶囊和片剂治疗轻中度阿尔采末病（ＡＤ）的疗效和不良反应。方法：９２例ＡＤ病人随机分２组，胶囊组５５例（男性２７例，女性 ２８例，年龄 ６９ ａ ± ｓ７ ａ）；片剂组 ３７例（男性１７例，女性 ２０例，年龄 ７１ａ± ６ａ）。给石杉碱甲胶囊或片剂 ０． １５ ｍｇ，ｐｏ， ｂｉｄ × ８ ｗｋ。结果：胶囊组和片剂组总有效率分别为 ６９％， ５７％，２组比较差异无显著意义（Ｐ＞０．０５）。结论：石杉碱甲是一个安全、有效的治疗ＡＤ药物，肢囊剂型与片剂剂型疗效相似。

AIM: To compare the clinical efficacies and adverse reactions of huperzine A capsules and tablets in treating Alzheimer disease(AD). METHODS: Ninety-two patients with mild to moderate AD were recruited. Fifty-five patients (M 27, F 28; age 69 a ± s 7 a) were treated with huperzine A capsule, 0. 15 ｍg,ｐｏ, bid for & wｋ and 37 patients (M 17, F 20; age 71 a± 6 a) were treated with huperzine A tablet, 0. 15 mg, po, bid for ８ wｋ. RESULT: The clinical efficacy was 69% in the huperzine A capsule group and 57% in the huperzine A tablet group (P > 0. 05 ). CONCLUSION: Huperzine A capsules is similar to huperzine A tablets in treating mild to mederate AD patients.